dtx

MobiHealthNews talks about the value of digital therapeutics, artificial intelligence and learnings from COVID-19 with Dr Cesar Morcillo Serra, director of internal medicine in Hospital Cima Sanitas Barcelona, Spain.

In response to recent COVID-19 guidance, the company is releasing its video game-like treatment to qualifying families at no cost, and without explicitly requiring a doctor's prescription.

Also: FDA COVID-19 policy allows for remote use, digital modifications to ophthalmic devices; 23andMe launches genetics study to understand varying COVID-19 responses.

Somryst, a prescription digital therapeutic combining cognitive behavioral therapy and personalized sleep restriction, is the first software product to put the FDA's early Precertification Program framework through its paces. 

New agreements with five different tech companies and research organizations aim to expand and flesh out the digital therapeutics maker's product pipeline.

The study, which was presented at the Meeting of the American College of Neuropsychopharmacology yesterday, found that patients using the technology improved their sustained attention compared to those in the control group. 

A new exploratory collaboration with Ironwood Pharmaceuticals comes just a couple weeks after the digital therapeutics startup ended a commercialization relationship with Novartis' Sandoz.

The pharma's Sandoz division will be handing commercialization of reSET, reSET-O and future therapies back to Pear over the course of a transition period.

MobiHealthNews sat down with Rock Health to discuss the future of digital health and pressing trends in this novel space. 

Digital therapeutic stakeholders came together at this week's DTx East conference to discuss the state of digital health investment, developing successful business models, the need for robust data and more.